Lunsekimig

DB19009InvestigationalProtein Based Therapies

Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).

Mechanism: Pharmacologically active on Interleukin-13 and Thymic stromal lymphopoietin
Curator reviewed
Code names: SAR-443765

Resolves to

Compound

UNIIVYR5R5XN5ACAS2770858-49-4

Targets

P35225IL13Q969D9TSLP

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lunsekimig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account